Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial
Main finding · HbA1c change from baselineResult — go to the resultChange from baseline −0.74 %Authors' conclusion
Modifying antiglycaemic treatment from a BOT regimen to iGlarLixi 100/33 in suboptimal controlled PwT2D in daily clinical practice improved glycaemic control without increasing hypoglycaemia and with favourable body weight change.
Study context
- Population
- PwT2D with HbA1c 7.5%-10.0% on basal insulin supported oral therapy (BOT), German primary care, switched by physician to iGlarLixi 100/3370 in full analysis set
- Participants
- 93 participants
- Exposure
- Switch from BOT to iGlarLixi 100/33
- Outcome
- Absolute change in HbA1c (%) from baseline
- Follow-up
- 24 weeks
Methodological detailsnon-interventional, multicentre, single-arm
- Non-interventional
- Multicentre
- Single-arm
Main finding
HbA1c change from baseline · approximately 24 weeks
Change from baseline
−0.74 %
P < 0.01
Change by group
iGlarLixi 100/33
−0.74
mean · SD 0.81 · %
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Values | Estimate | P value |
|---|---|---|---|
| FPG change from baseline · ≈24 weeks | iGlarLixi 100/33 mean −32.9 (SD 46.3) mg/dL · baseline 174.3 ± 44.6 mg/dL · 24 weeks 141.4 ± 34.1 mg/dL | change from baseline −32.9 mg/dL | P < 0.01 |
| Body weight change from baseline · ≈24 weeks | iGlarLixi 100/33 mean −3.0 (SD 7.5) kg · baseline 104.3 ± 22.5 kg · 24 weeks 101.3 ± 21.6 kg | change from baseline −3.0 kg | P < 0.01 |
Use of DPP-4i
- Use of DPP-4i significantly reduced, from baseline to follow-up
- 34.8% to 6.8%
Derived time in range (TIR) and time above range (TAR) (7-point SMBG) · 24 weeks
- TIR increased and TAR decreased to target ranges (all p < 0.05)
Flash glucose monitoring (20 patients)
- Similar patterns for TIR and TAR; reduction in TBR
- P = 0.007
Safety
Hypoglycaemia · 24 weeks
- Hypoglycaemia events did not change significantly and were low in number
- No severe hypoglycaemia was reported
Original publication
Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial. Diabetes Obes Metab. Published 6 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →